Background: Specific binding to target protein epitopes by a mouse monoclonal antibody (mAb) relies on its variable domains. However, the isolation of functional variable gene transcripts is sometimes hindered by co-expression of aberrant transcripts in hybridoma cells.
Introduction
Hybridoma technology is used to produce monoclonal antibodies (mAbs) by fusion of murine B cells and myeloma cells. However, some hybridoma clones may lose the ability to produce mAb due to genetic instability and/or inappropriate culturing and storage conditions. Thus, archiving of variable genes should be performed for safekeeping of valuable clones. In addition, mouse variable genes can be fused to the constant
Identification of aberrant variable gene transcripts and gene cloning
The V κ PCR products were subsequently digested with BciVI (NEB) restriction enzyme. The 400 bp BciVI-resistant V κ as well as the 500 bp V H PCR products were cloned into the pGEM-T TA cloning vector (Promega). Plasmids containing V H or V κ gene were purified from transformed E. coli strain DH5α bacteria and verified by DNA sequencing. Plasmids with cloned V H or V κ sequences were analyzed with BLAST and the IMGT V-QUEST database tool (http://www.imgt.org/IMGT_vquest/ vquest).
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Construction of dual antibody expression plasmid
The dual expression plasmid containing HER2/neu receptor specific humanized IgG1/κ antibody isotype (pVITRO1-hTrastuzumab-IgG1κ), a gift from Andrew Beavil (Addgene plasmid # 61883), was used. Variable domains of the HER2/ neu receptor in the dual plasmid were replaced with V H and V κ genes derived from mAbs using the polymerase incomplete primer extension (PIPE) technique. 12 Briefly, pVITRO1-hTrastuzumab-IgG1κ was amplified to obtain two linearized plasmid fragments by PCR using two vector-specific primer pairs (Linear_Kfwd/Linear_Hrev and Linear_Hfwd/Linear_ Krev; (Table S3) . V H and V κ genes cloned in pGEM-T plasmid vector were amplified with specific primer pairs for each mAb region of an immunoglobulin gene derived from another species in order to generate chimeric antibodies (chAbs), which are useful for various applications. For example, chAbs are used therapeutically in humans, in which the variable genes are fused to the human immunoglobulin backbone to minimize irrelevant immunogenicity. To date, a number of chAbs have been used for treatment of disease, e.g. Rituxan (rituximab) for rheumatoid arthritis and Remicade (Infliximab) for auto-immune diseases. 1, 2 For the generation of chAbs, it is necessary to clone genes encoding V H and V κ of target mAbs from mouse hybridoma cell lines. However, aberrant immunoglobulin mRNAs are found in hybridoma cells derived from MOPC21 myeloma fusion partners, which interfere with the cloning of the desired variable gene transcripts. Aberrant V κ sequences frequently contain a premature stop codon at a position 105 and the codon replacement of cysteine to tyrosine at position 23. 3 Several strategies have been applied to eliminate aberrant V κ transcripts, such as peptide sequencing and antisense directed RNase H to digest the aberrant V κ mRNA, but these strategies are ineffective. 4 However, most aberrant V κ sequences contain recognition sites for some restriction endonucleases. 5 A BciVI site, for example, is commonly located in aberrant transcript sequences (96%). Therefore, BciVI-sensitive aberrant V κ can be distinguished from the BciVI-resistant sequences that encode functional V κ . However, since the aberrant V κ transcripts in most myeloma partners are abundant and preferentially amplified, a rare functional V κ genes are then hardly to be recovered after BciVI digestion, which still allowed low efficiency in downstream cloning step. 6 We have generated several mouse hybridoma clones producing mAbs against dengue virus proteins, which are useful for immunopathology of dengue diseases, diagnostics and dengue vaccine development. We wished to clone V H and V L genes from these valuable hybridoma clones as genetic archive in case the cells lose viability. Moreover, the cloned immunoglobulin genes are required to generate chAbs. The presence of aberrant V κ transcripts in these clones could prevent the isolation of the desired functional genes. In this study, we proposed a strategy to select functional variable transcripts from murine hybridoma clones by using two sets of specific primers covering most of the mouse immunoglobulin genes to selectively amplify different V H or V κ gene sequences. PCR products from aberrant V κ transcripts can be identified by BciVI digestion. Functional transcript sequences of variable domains could be selectively amplified from 17 hybridoma cell lines producing antibodies against dengue virus proteins (NS1, nonstructural protein 1; E, envelope; and prM, pre-membrane). Functional V H and V κ genes of three hybridoma cell lines with the human IgG1 constant region were assembled to generate chAbs. The functional properties of the chAbs were compared with the corresponding original mAbs.
Methods
Hybridoma cells and viruses
Seventeen mouse hybridoma cell lines producing mAbs against dengue prM, E and NS1 proteins were used in this study. Most of them were generated from X63-Ag8.653 myeloma fusion partner, except 4G2 and 2H2 which were from Table S3 ). Four PCR fragments with overlapping ends were mixed and annealed to make circular plasmids at 50ºC for 1 hour, and then treated with the restriction enzyme DpnI (NEB). The assembled PCR products were transformed into E. coli strain DH5α. The pVITRO1 plasmids containing the cloned V H and V κ genes for production of antibodies against dengue proteins were validated by nucleotide sequencing (Macrogen). 
Transfection and recombinant antibody production
Two μg of a plasmid encoding V H and V κ transcripts was transfected into human embryonic kidney cell line 293T (ATCC, USA) with Lipofectamine 2000 (Thermo Fisher, USA). Supernatants containing chAbs were harvested to assay for expression.
Results
Coexpression of functional and aberrant V κ transcripts in murine hybridoma cells
Three hybridoma clones (2G6, 1F11 and 1A4) producing mAbs against dengue NS1 proteins were selected for initial characterization of V κ genes. V κ PCR products of the expected size (400 bp) were obtained using a mixture of leader light chain primers and a constant kappa light chain primer ( Table  S2) . Analysis of cloned nucleotide sequences indicated that only the 2G6 clone V κ sequence could produce functional antibody protein. In contrast, V κ sequences from clones 1F11 and 1A4 contained a stop codon at a position 105 and Tyr at position 23, the hallmarks of aberrant V κ genes. These aberrant V κ sequences were identical to those of several hybridoma clones derived from the X63-Ag8.653 myeloma cell line as previously reported. 3, 13 As a BciVI recognition site is commonly found in aberrant V κ genes, we hypothesized that mouse hybridoma clones with functional or aberrant V κ genes could be distinguished by digestion of V κ gene PCR products with BciVI. As expected from sequence analysis, the PCR product from clone 2G6 was resistant to BciVI treatment, but an additional digested 200 bp DNA fragment was observed from the 1F11 and 1A4 clones producing aberrant V κ ( Figure 
Characterization of chAbs
The obtaining chAbs were characterized for the presence of human immunoglobulin and their specific reactivity to dengue NS1. The human immunoglobulin of chAbs were tested by dot blot analysis using HRP-conjugated goat anti-human immunoglobulins (Jackson Immuno Research, USA), specific to human immunoglobulin. To determine specific binding reactivity in comparison with mAbs, DENV1 to 4 -infected cell lysates or supernatants were tested with chAbs by dot blot assay and Western blot analysis. For secondary or conjugated antibody, HRP-conjugated goat anti-human immunoglobulins was used followed by chAbs, whereas, HRP-conjugated anti-mouse Igs (Dako, USA) was followed by mAbs. Antibody reactivity on DENV1 to 4 -infected cells was also tested by immunofluorescent assay (IFA), in which anti-E mAb (m4G2) was used to confirm dengue virus infection.
Competitive binding ELISA
The purified NS1 protein from DENV2 infected Vero cells (10 ng) was coated on ELISA wells. The blocking mAb was initially added to NS1-coated ELISA wells from 0.17 to 100 µg/ ml (100 µl) for 1 hour. PBS was used as negative control. The chAb was subsequently added to those ELISA wells to obtain a final concentration of 6 µg/ml for another 1 hour. The bound chAb-NS1 complex was detected with goat-anti-human IgG-HRP (dilution 1:1000; P214, Dako). The TMB substrate (Thermo Fisher Scientific, USA) was used to develop reaction colors and OD reading at 450 nm (A450) was measured by ELISA reader. The percentage of blocking (% blocking) were calculated as followed:
% Blocking of chAb = (A450 of control well -A450 of the test well) × 100/A450 of control well Where control well is A450 obtained from chAb without blocking antibody (no mAb). Test well is A450 obtained from chAb reactivity in the presence of blocking mAb (+mAb). (200 bp)). PCR products of anti-NS1 antibody clones were separated in lanes 2-15 (clone identifiers shown above the lanes), whereas PCR products of anti-E (4G2) and anti-prM (2H2) antibody clones were separated in lane 16 and 17, respectively.
Functional V κ genes from clones coexpressing aberrant V κ genes
From the coexpression of functional and aberrant V κ transcripts, we hypothesized that the functional V κ transcripts could be selectively PCR-amplified using different sense primers binding to variable regions. Each of eight different sense primers (LVk) with a constant kappa light chain anti-sense primer were initially tested for PCR amplification using cDNA from three clones (1F11, 1A4 and 2G6). The 400 bp V κ PCR product was obtained by some, but not all individual primers from each clone (Figure 2A ). Subsequent treatment with BciVI was performed to distinguish functional V κ genes PCR products (resistant to digestion) from aberrant V κ genes (sensitive to digestion) ( Figure 2B) . The BciVI-resistant products from 2G6 (obtained using primer LVk20), and these from 1F11 and 1A4 (obtained using primer LVk6) were cloned. Sequencing of the cloned V κ genes demonstrated that all cloned genes encoded functional V κ as expected. The same experimental protocol was applied to the other hybridoma clones, and BciVI-resistant V κ amplicons were obtained using different sense primers (Figure S2) . Sequencing of these BciVI-resistant V κ gene products showed that all encoded functional V κ gene sequences. A few exceptions were found in clones 4G2 and 2H2 in which these Table S2 ) and separated by agarose gel electrophoresis (clones indicated in each panel below the lanes). The PCR products were either left untreated (-) or treated with BciVI (+), prior to electrophoresis. Amplicon undigested with BciVI corresponds to putatively productive V κ gene (marked as Undigested (400 bp)), whereas BciVI-digested amplicon corresponds to putatively aberrant V κ gene (marked as Digested (200 bp)). Lane M represents standard DNA markers (bp). V κ gene products amplified by primer LVk689, but not the others, were identified as endogenous V κ genes from myeloma cells (Table S4) . These results suggested that the protocol for obtaining functional V κ genes is reproducible among different mouse hybridoma clones.
Amplification of V H transcripts
PCR amplification of the V H gene was initially tested from three hybridoma clones (2G6, 1F11 and 1A4). 500 bp V H gene products were obtained by semi-nested PCR using different V H primer pairs (Figure 3) . Sequencing analysis indicated that all cloned V H genes encoded functional antibody proteins. V H transcripts of the other 14 hybridoma clones were PCR amplified in the same manner ( Figure S3 ) and verified by sequencing analysis. Functional V H transcripts were obtained from all hybridoma clones, except 1B2 of which the aberrant sequence was generated by a frameshift at the CDR3 region. The aberrant V H sequence from 1B2 is not described in previous reports. 6, 14 Therefore, we deposited this novel aberrant V H sequence in the GenBank database (GenBank accession no. MF174854). 
Generation and functional testing of chAbs
To verify the functionality of cloned V H and V κ genes, chAbs containing mouse variable region and human IgG1 constant region were generated. The putatively functional V H and V κ genes obtained from mouse hybridoma clones 2G6, 1F11 and 1A4 were sub-cloned into the dual expression plasmid pVITRO/ IgG1κ. Recombinant plasmids were transfected to 293T cells. Three transfected cell lines were established that secreted chAbs to dengue NS1 protein, designated as ch2G6/IgG1κ, ch1F11/ IgG1κ, and ch1A4/IgG1κ. The human IgG1 constant region of these chAbs cross-reacted with anti-human immunoglobulins (Igs)-HRP, but not with anti-mouse Igs-HRP, by dot blot assay ( Figure S4A ). In addition, by competitive binding ELISA, we showed that NS1 binding of ch1F11 and ch1A4 Abs can be blocked by their original mAbs, but not by other clones ( Figure  S4B ). This result indicated the same recognition epitope on NS1 protein of original mAb and its corresponding chAb. Functional assays were performed to test the activity of chAbs against dengue NS1 proteins in comparison with the original mouse mAbs (m2G6, m1F11 and m1A4). By immunoblotting, the (DENV1-4) . NS1 staining (green) was performed with either a mouse monoclonal antibody (mAb) (2G6, 1F11 or 1A4), followed with goat anti-mouse IgG-Alexa 488 or their chimeric counterpart (chAb/IgG1κ), followed with goat anti-human IgG-Alexa 488. Infectivity was confirmed by staining the dengue virus E protein with m4G2 (green). Hoechst33342 dye (blue) was used to stain cell nuclei. Cell staining was observed under EVOS cell imaging systems, at magnification of 20 (20x). Figure S4 . A) Detection of human IgG1 constant region in chimeric antibodies. Chimeric (ChAb) and mouse (mAb) antibodies were dotted onto a nitrocellulose membrane for a dot blot assay. Either HRP-conjugated rabbit anti-mouse Igs or HRP-conjugated goat anti-human IgG was added to detect host isotype specificity. B) The original mAb blocks NS1 binding of corresponding chAb by a competitive binding ELISA. The blocking mAb (m2G6, m1F11or m1A4) was initially bound to DENV2 NS1-coated ELISA wells at various concentrations. The chAb (ch1A4 or ch1F11) was subsequently added to compete NS1 binding with those blocking mAbs. The percentage of blocking of ch1A4 or ch1F11 were analyzed and plotted against various concentration of blocking mAb. The higher efficient blockage (% blocking) suggested higher degree of overlapped epitope, or even the same epitope, as recognized by two competitive antibodies (ch1A4/m1A4 or ch1F11/m1F11). In contrast, lower % blocking suggested the discrete or non-overlapped epitopes of the two antibodies (ch1A4/m2G6 or ch1F11/m1A4 and ch1F11/m2G6). ch2G6/IgG1κ and ch1A4/IgG1κ chAbs reacted with DENV2 NS1 proteins, similar to the corresponding m2G6 and m1A4 antibodies, whereas the ch1F11/IgG1κ chAb recognized NS1 proteins of all four dengue serotypes, similar to the corresponding m1F11 (Figure 4) . The three chAbs were tested for NS1 detection in dengue-infected fixed cells by IFA ( Figure 5 ). Similar staining patterns to the original mouse hybridoma clones were found, in which the ch1F11 antibodies bound to NS1 proteins located in the cytoplasm of all dengue-infected cells, whereas ch1A4 antibodies recognized NS1 in DENV2-infected cells. Moreover, the ch2G6 antibodies strongly detected NS1 proteins in DENV2-infected cells, with weaker detection in DENV1-infected cells. None of the chAbs showed non-specific binding to mock-infected cells.
Discussion
The occurrence of endogenous aberrant variable transcripts, in particular V κ gene transcripts in murine hybridoma cells presents an obstacle for manipulation of antibodies. Several strategies, including restriction enzyme digestion, for example BCiVI, to eliminate aberrant transcripts have not been fully effective because these transcripts may be expressed at similar or higher levels than the functional ones. To our experience, we initially amplified 1F11 V κ PCR products using the mixed primers covering all mouse immunoglobulin families and directly cloned to TA cloning vector without BCiVI digestion, but all selected transformants contained only undesirable aberrant transcripts. Another attempt was done according to Ding's method by using the same 1F11 V κ PCR products, but followed with BCiVI digestion. 6 The proportion of BCiVI-resistant PCR product (supposed to be functional V κ ) was much lower than the digested one (supposed to be aberrant V κ ) as demonstrated by agarose gel electrophoresis ( Figure 1B primers, instead of the mixed primers, followed by BCiVI treatment to differentiate the functional V κ gene from the aberrant one. By this strategy, the BCiVI-resistant, functional V κ PCR products were much easily obtained and could be directly cloned. Interestingly, those functional V κ genes of each mouse hybridoma cell lines were found in all selected transformants (Table S4) , suggesting highly success rate of V κ gene cloning. Mouse immunoglobulin (Ig) genes are highly diverse in sequence. 13, 15 In this study we showed that 14 of 17 hybridoma clones, except 2G6, 1B10 and 2H2, contained BciVI-aberrant V κ genes when the mixed V κ primers were used (as shown by BciVI-digested products in Figure 1B) . Some of them obviously demonstrated high proportion of aberrant V κ over functional V κ (clone 1F11, 4D4, 2D3, Figure 1B) . It is suggested that the expression of aberrant V κ is predominant in mouse hybridoma clones. This observation is concordant with other studies describing preferential amplification of aberrant V κ cDNAs from mouse hybridoma cells despite using different sets of primers. 5, 6 Nevertheless, we demonstrated that BciVI-resistant amplicons could be obtained according to our selective primers strategy and functional V κ genes were cloned for all 17 hybridoma clones in this study ( Table S4 ).
Noted that BciVI-resistant amplicons were obtained using sense primers LVk5, LVk6, LVk19, LVk20 and LVk689 that varied among hybridoma clones; however, BciVI-sensitive amplicons were obtained using primers LVk3 and LVk14 (Figure  2 and S2) . The latter two primers shared 17/21 nucleotides to each other, and are most similar to the leader sequence of the aberrant V κ transcript reported previously, explaining why aberrant V κ gene are frequently amplified by these two primers. 3, 16 Being different from the others, the BciVI-resistant amplicon obtained from clones 4G2 and 2H2 using primer LVk689 (Table  S4 ) was identified as endogenous MOPC21 kappa light chain transcript (GenBank accession no.V00810). 17 In the early days of hybridoma technology development, mouse myeloma P3-X63-Ag8 derived from MOPC21 tumor cells was used for fusion with mouse B-cells. This immortal myeloma expresses and secretes MOPC21 immunoglobulin, which interferes with hybridoma clone immunoglobulin production. 18 Therefore, we suspect that these endogenous V κ transcripts are produced from the parental mouse myeloma fusion partner (P3-X63-Ag8) which was used to generate 4G2 and 2H2 hybridoma clones. 7, 8 The LVk689 primer sequence matches the V region of MOPC21 Ig kappa light chain, and thus is expected to prime amplification of endogenous MOPC21 transcripts that may be present. In contrast, subclones of P3-X63-Ag8, such as Sp2/0-Ag14, and P3-X63-Ag8.653, were later developed to eliminate the secretion of this endogenous immunoglobulin and are still commonly used for generating hybridomas. 18 No MOPC21 or endogenous immunoglobulin transcript sequences were obtained from the other 15 hybridoma clones (Table S4) , as they were generated from a non-secreting immunoglobulin myeloma fusion partner P3-X63-Ag8.653. 9, 10 For V H genes, 500 bp amplicons of functional transcripts were obtained from one or more primer pairs from all hybridoma cells used in this study. The one notable exception is the aberrant 1B2 V H transcript, which contains a premature stop codon at the beginning of CDR3, leading to a non-productive heavy chain variable region. In general, aberrant V H transcripts are rarely reported. V H aberrant sequences are more diverse than aberrant V κ . Two aberrant V H transcripts (abVH-HF3, GenBank accession no. EU121635; abVH-HF4, GenBank accession no. EU121634) in the myeloma fusion partner P3-X63-Ag8.653 were previously reported by Yazad Irania et. al. 14 The aberrant V H transcripts abVH-HF3 and abVH-LF8 (GenBank accession no. HM046413.1) are 98% identical and share the same change in the reading frame in the VDJ joining region encoding CDR3 (different from 1B2 V H ), whereas abVH-HF4 . V H and V κ amplification strategy. Murine hybridoma cells were used as sources of immunoglobulin variable domains V H and V κ . RNA was extracted and reverse transcribed to generate first strand cDNA. V H was amplified with a panel of five sense primers together with a common antisense primer in separate reactions, and the 500 bp PCR products were cloned into the TA plasmid. V κ was amplified with eight individual sense primers and a common antisense primer in separate reactions, and the 400 bp PCR products were digested with BciVI. Digested amplicons were identified as aberrant V κ transcripts and only undigested amplicons of putatively productive V κ transcripts were cloned into the TA plasmid. Plasmids containing V H or V κ sequences were analyzed with the IMGT database tool.
Identification of functional variable gene transcripts from mouse hybridomas
harbors a 50 bp deletion in the same region. 6, 14 The diversity of aberrant V H transcripts hindered the development of general strategies to select the functional gene for further cloning step.
The putatively productive variable genes cloned from PCR products were verified as functional chAbs with the human Ig-G1κ backbone. The binding properties of ch2G6, ch1F11 and ch1A4, as well as recognition epitopes are indistinguishable from the original mAbs by various assays (Figure 4 and 5, Figure S4B) . These results validated our protocol, as summarized in Figure 6 for identifying functional antibody transcripts from mouse hybridoma clones which coexpress aberrant genes.
In conclusion, we have developed a simple method for cloning variable gene transcripts for both V H and V κ that is reproducible in different mouse hybridoma cells by using 8 individual primer pairs covering most of the mouse immunoglobulin genes. Screening of BciVI-resistant V κ PCR product is a quick and easy way to identify functional V κ transcripts and reduce the tedious downstream steps of cloning and selection. This approach is promising for the generation of chAbs as well as genetic archiving of valuable mouse hybridoma clones, which is beneficial for therapeutics and other medical applications.
